Talking Post-Transplant Acute Myeloid Leukemia: Improving Outcomes After Relapse

Thursday, November 17, 2022, 3:00 PM - Tuesday, October 31, 2023, 11:59 PM

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)


Despite continual progress in the treatment and management of acute myeloid leukemia (AML), relapse rates following allogeneic stem cell transplantation remain unacceptably high and a major cause of death. There have been various attempts to improve outcomes in this setting of AML which need to be integrated on a case-by-case basis.

This archived series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation relapse in AML.

There are no fees for participating.

Click 'register now' to access this activity.

1. Examine the need to improve outcomes in post-transplantation relapse in acute myeloid leukemia (AML) patients;
2. Identify methods to detect post-transplantation relapse accurately and in a timely manner;
3. Evaluate the potential of novel maintenance and salvage therapies in improving outcomes in post-transplantation relapse and/or preventing it;
4. Implement individualized approaches to effectively treat and manage patients with post-transplantation relapse.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The staff planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity. The noted relationships below have been mitigated and not relevant to this presentation.

STAFF PLANNING COMMITTEE DISCLOSURES

Practice Point Communications
Nirupama Mulherkar
Martin Stevens
Jill Valone

University of Cincinnati
Robert Ellis, MD
Susan Tyler, PhD
Heather Muskopf

The University of Cincinnati and Practice Point Communications and the peer/content reviewers for this activity have no relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor Practice Point Communications, recommends the use of any agent outside of the labeled indications.

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24-months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education, or whose conflicts of interests cannot be mitigated.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity. The noted relationships below have been mitigated and not relevant to this presentation.

Faculty Disclosures

Gail Roboz, MD (Course Director)
Professor of Medicine
Weill Cornell Medicine
New York, New York

Consultant, Advisory Board, Data and Safety Monitoring Committee: AbbVie, Agios, Amgen, Astellas, AstraZeneca, Bluebird Bio, Blueprint Medicines, Bristol Myers Squibb, Catamaran, Celgene, GlaxoSmithKline, Helsinn, Janssen, Jasper Therapeutics, Jazz, Mesoblast, Novartis, Pfizer, Roche, Syndax, Takeda(IRC Chair)
Research Support: Janssen

Daniel Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H. Allen MD Endowed Chair in Hematology Research
Division of Hematology, Department of Medicine
University of Colorado School of Medicine
Aurora, Colorado

Advisory Board Member: AbbVie, Aprea, Arcellx, Astellas, AstraZeneca, BeiGene, BergenBio, Bristol Myers Squibb, Foghorn, Genentech, Jazz Pharmaceuticals, Karyopharm, Kiadis, Kura, Magenta, Novartis, Qihan, Ryvu, Syndax, Syros, Zentalis
Consultant: AbbVie, Genentech, Gilead, Karyopharm, Novartis, Syros, Takeda
Research: AbbVie, Bristol Myers Squibb, Karoypharm

Keith Pratz, MD
Director of Leukemia
University of Pennsylvania
Philadephia, Pennsylvania

Consultant: AbbVie, Agios, Astellas, BMS/Celgene, Jazz Pharmaceuticals, Servier
Research Support: AbbVie, Agios, Astellas, Millenium

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

This educational activity is supported by an educational grant from Astellas and Bristol Myers Squibb.